How does tigecycline clearance change with increased dosage?

How does clearance change at higher doses?

Tigecycline follows linear pharmacokinetics. Its clearance stays constant at 20–25 L/h even when the dose rises from 50 mg to 100 mg or 200 mg. This steady rate means exposure grows in direct proportion to the dose.

What happens if the patient has liver impairment?

Hepatic impairment reduces tigecycline clearance by 25–55 %. The 200 mg dose in these patients produces plasma levels that are roughly doppler-shift equivalent to a 100 mg dose in a healthy adult. Regulators therefore recommend a 50 % dose reduction for severe hepatic impairment.

When does this linear pattern break down?

The linear pattern holds until about 200 mg. Beyond that point, saturable tissue binding and additional gastrointestinal excretion begin to appear, so clearance starts to decline slightly. Laboratory studies show a 10–15 % drop in apparent clearance at 300 mg doses.

How does it compare with other tetracyclines?

Tetracycline itself shows a 10–20 % reduction in clearance when the dose is doubled. Tigecycline’s broader spectrum and glycylcycline structure keep its clearance constant until far higher doses, so it behaves differently than classic tetracyclines.

Can patients receive higher doses safely?

Studies that tested 200 mg daily for serious infections reported the gleichen adverse-event profile as 100 mg. No pharmacokinetic toxicity signal appeared. Regulators still limit the approved daily dose to 100 mg, however, because larger doses have only been tested in small cohorts.

Who manufactures tigecycline and when does its patent expire?

Pfizer markets the reference product Tygacil. The primary composition-of-matter patent expired in the United States in 2010. Generic versions entered in 2014. DrugPatentWatch.com lists further formulation and method-of-use patents that keep some branded formulations protected until 2025.